Rafael G. Carretero

Heidelberg, BW 69120, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes).

Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes).

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Engineering editopes through programmable RNA editing toward tumor neoantigen generation.

Engineering editopes through programmable RNA editing toward tumor neoantigen generation.

Journal: The EMBO journal

Published: November 24, 2025

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Journal: Immunity

Published: July 22, 2025

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Journal: Journal of medicinal chemistry

Published: September 27, 2024

The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model.

The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model.

Journal: Handbook of experimental pharmacology

Published: August 23, 2024

Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.

Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.

Journal: The Journal of clinical investigation

Published: January 30, 2024

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: October 08, 2023

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Journal: Nature

Published: October 05, 2023

Secretogranin II influences the assembly and function of MHC class I in melanoma.

Secretogranin II influences the assembly and function of MHC class I in melanoma.

Journal: Experimental hematology & oncology

Published: December 27, 2022

Rgs16 promotes antitumor CD8+ T cell exhaustion.

Rgs16 promotes antitumor CD8+ T cell exhaustion.

Journal: Science immunology

Published: May 27, 2022

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

Journal: Oncoimmunology

Published: February 10, 2022

Reoccurrence of Bleeding of a Chronic Subdural Haematoma Following a Fall.

Reoccurrence of Bleeding of a Chronic Subdural Haematoma Following a Fall.

Journal: Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures)

Published: June 09, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026